Log in to your Inderes Free account to see all free content on this page.
Nanoform Finland
2.51 EUR +1.83%3,389 investors are following this company
Nanoform Finland is a medical technology company. The company specializes in the research and development of technical products used to create nanoparticles in pharmaceuticals. The technology is used as a complement in the production process and is used for the treatment of diseases such as ALS and Alzheimer's. The customers consist of companies in the global pharmaceutical industry. Nanoform Finland mainly operates in the Nordic market and is headquartered in Helsinki.
Revenue
2.57M
EBIT %
-874.71 %
P/E
-
Dividend yield-%
-
Target price
-
Recommendation
-
Updated
-
First North Finland
NANOFH
Daily low / high price
2.395 / 2.57
EUR
Market cap
196.9M EUR
Turnover
45.58K EUR
Volume
19K
Latest videos
Financial calendar
Interim report
30.05.2024
Interim report
29.08.2024
Interim report
22.11.2024
Annual report
27.02.2025
Major OwnersSource: Millistream Market Data AB
Owner | Capital | Votes |
---|---|---|
Handelsbanken | 7.7 % | 7.7 % |
Edward Hæggström | 6.9 % | 6.9 % |
Premium
This content is for our Premium customers only.
ShowingAll content types
Resolutions of Nanoform Finland Plc's Annual General Meeting on April 16, 2024
Nanoform Enters Exclusive Partnership with CBC to Bring Best-in-Class Nanomedicine Technology to Japan
Join Inderes community
Don't miss out - create an account and get all the possible benefits
FREE account
Stock market's most popular morning newsletter
Analyst comments and recommendations
Stock comparison tool
PREMIUM account
All company reports and content
Premium tools (e.g. insider transactions & stock screener)
Model portfolio